TY - JOUR
T1 - Kinetic characterization of ASXL1/2-mediated allosteric regulation of the BAP1 deubiquitinase
AU - Peng, Hongzhuang
AU - Cassel, Joel
AU - McCracken, Daniel S.
AU - Prokop, Jeremy W.
AU - Sementino, Eleonora
AU - Cheung, Mitchell
AU - Collop, Paul R.
AU - Polo, Alexander
AU - Joshi, Surbhi
AU - Mandell, Jacob P.
AU - Ayyanathan, Kasirajan
AU - Hinds, David
AU - Malkowicz, S. Bruce
AU - Harbour, J. William
AU - Bowcock, Anne M.
AU - Salvino, Joseph
AU - Kennedy, Eileen J.
AU - Testa, Joseph R.
AU - Rauscher, Frank J.
N1 - Funding Information:
We thank Katherine L.B. Borden and Michael Osborne (University of Montreal) for their advice and suggestions related to this project and article. This work was supported by NCI grants R01CA175691 (to J.R. Testa and F.J. Rauscher), P30CA006927 (Fox Chase Cancer Center); P30CA010815 and R01CA163761 (to F.J. Rauscher), and NIH Office of the Director grant K01ES025435 (to J.W. Prokop). Support for Shared Resources was provided by P30CA010815 to The Wistar Institute. Also supported by the Jayne Koskinas Ted Giovanis Foundation for Health and Policy (to F.J. Rauscher), the Palmira and James Nicolo Family Research Fund (to S.B. Malkowicz), Local #14 Mesothelioma Fund of the International Association of Heat and Frost Insulators and Allied Workers (to J.R. Testa), Samuel Waxman Cancer Research Foundation (to F.J. Rauscher), and the office of the assistant secretary of Defense for Health Affairs, through the Breast Cancer Research Program, under award numbers W81XWH-17-1-0506, W81XWH-14-1-0235, and W81XWH-11-1-0494 (to F.J. Rauscher). This work was also supported by grants 1K22A154600 and 1R03A188439 (to E.J. Kennedy).
Funding Information:
M. Cheung reports a patent for US10344333B2 issued. J. Harbour reports other support from Castle Biosciences during the conduct of the study, as well as a patent for Washington University issued, licensed, and with royalties paid from Castle Biosciences. A.M. Bowcock reports a patent for 9,133,523 licensed and with royalties paid from Castle Biosciences. J.R. Testa reports grants from NCI and from the Local #14 Mesothelioma Fund of the International Association of Heat and Frost Insulators and Allied Workers during the conduct of the study, has been a legal consultant regarding genetic aspects of mesothelioma susceptibility, and reports a patent for diagnosing a predisposition to cancer due to germline alterations of BAP1. No disclosures were reported by the other authors.
Publisher Copyright:
© 2021 American Association for Cancer Research.
PY - 2021/7
Y1 - 2021/7
N2 - BAP1 is an ubiquitin hydrolase whose deubiquitinase activity is mediated by polycomb group-like protein ASXL2. Cancer-related BAP1 mutations/deletions lead to loss-of-function by targeting the catalytic ubiquitin C-terminal hydrolase (UCH) or UCH37-like domain (ULD) domains of BAP1, and the latter disrupts binding to ASXL2, an obligate partner for BAP1 enzymatic activity. However, the biochemical and biophysical properties of domains involved in forming the enzymatically active complex are unknown. Here, we report the molecular dynamics, kinetics, and stoichiometry of these interactions. We demonstrate that interactions between BAP1 and ASXL2 are direct, specific, and stable to biochemical and biophysical manipulations as detected by isothermal titration calorimetry (ITC), GST association, and optical biosensor assays. Association of the ASXL2-AB box greatly stimulates BAP1 activity. A stable ternary complex is formed, comprised of the BAP1-UCH, BAP1-ULD, and ASXL2-AB domains. Stoichiometric analysis revealed that one molecule of the ULD domain directly interacts with one molecule of the AB box. Real-time kinetic analysis of the ULD/AB protein complex to the BAP1-UCH domain, based on surface plasmon resonance, indicated that formation of the ULD/AB complex with the UCH domain is a single-step event with fast association and slow dissociation rates. In vitro experiments validated in cells that the ASXL-AB box directly regulates BAP1 activity. Implications: Collectively, these data elucidate molecular interactions between specific protein domains regulating BAP1 deubiquitinase activity, thus establishing a foundation for small-molecule approaches to reactivate latent wild-type BAP1 catalytic activity in BAP1-mutant cancers.
AB - BAP1 is an ubiquitin hydrolase whose deubiquitinase activity is mediated by polycomb group-like protein ASXL2. Cancer-related BAP1 mutations/deletions lead to loss-of-function by targeting the catalytic ubiquitin C-terminal hydrolase (UCH) or UCH37-like domain (ULD) domains of BAP1, and the latter disrupts binding to ASXL2, an obligate partner for BAP1 enzymatic activity. However, the biochemical and biophysical properties of domains involved in forming the enzymatically active complex are unknown. Here, we report the molecular dynamics, kinetics, and stoichiometry of these interactions. We demonstrate that interactions between BAP1 and ASXL2 are direct, specific, and stable to biochemical and biophysical manipulations as detected by isothermal titration calorimetry (ITC), GST association, and optical biosensor assays. Association of the ASXL2-AB box greatly stimulates BAP1 activity. A stable ternary complex is formed, comprised of the BAP1-UCH, BAP1-ULD, and ASXL2-AB domains. Stoichiometric analysis revealed that one molecule of the ULD domain directly interacts with one molecule of the AB box. Real-time kinetic analysis of the ULD/AB protein complex to the BAP1-UCH domain, based on surface plasmon resonance, indicated that formation of the ULD/AB complex with the UCH domain is a single-step event with fast association and slow dissociation rates. In vitro experiments validated in cells that the ASXL-AB box directly regulates BAP1 activity. Implications: Collectively, these data elucidate molecular interactions between specific protein domains regulating BAP1 deubiquitinase activity, thus establishing a foundation for small-molecule approaches to reactivate latent wild-type BAP1 catalytic activity in BAP1-mutant cancers.
UR - http://www.scopus.com/inward/record.url?scp=85109463073&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109463073&partnerID=8YFLogxK
U2 - 10.1158/1541-7786.MCR-20-0080
DO - 10.1158/1541-7786.MCR-20-0080
M3 - Article
C2 - 33731362
AN - SCOPUS:85109463073
SN - 1541-7786
VL - 19
SP - 1099
EP - 1112
JO - Molecular Cancer Research
JF - Molecular Cancer Research
IS - 7
ER -